News
-
-
PRESS RELEASE
Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons
Prof. Dr. Wiltrud Treffenfeldt resigns from Supervisory Board of BRAIN Biotech AG for personal reasons. Search for successor initiated. Company specializes in industrial biotechnology solutions -
-
-
PRESS RELEASE
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
BRAIN Biotech AG concludes a major pharma compound transaction valued up to EUR 128.88 million, monetizing royalty rights with Royalty Pharma for investigational compound deucrictibant from BioIncubator -
PRESS RELEASE
EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma
BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma -
-
PRESS RELEASE
BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year
BRAIN Biotech AG reports strong cash position for 9M period, forecasting growth in Q4 FY 23/24. BioProducts segment turnover slightly up, BioScience segment facing decline -
-
PRESS RELEASE
BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes
BRAIN Biotech AG appoints Erik de Vries as Senior Business Development Director Enzymes. De Vries will transition from CEO of Enzymicals AG to BRAIN Biotech's Supervisory Board in 2025
